Worsening schizoaffective disorder with aripiprazole [3]

American Journal of Psychiatry

Volumn 161, Issue 7, 2004, Pages 1308-

  Reeves, Roy R ^a   Mack, James E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM;

ADULT; AGITATION; AUDITORY HALLUCINATION; CASE REPORT; CLINICAL FEATURE; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; GRANDIOSE DELUSION; HUMAN; IMPULSE CONTROL DISORDER; LETTER; MALE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SYMPTOM; TREATMENT FAILURE;

EID: 3042699593     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.161.7.1308     Document Type: Letter

References (2)

1. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW: Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63:763-771
2. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P: A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57:553-559